tirzepatide cvot results Comparison of and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics SURPASS-CVOT: Tirzepatide Bests Dulaglutide for
Description
Your healthcare provider will help you determine the best course of action, whether thats continuing with the medication at a lower dose or switching to a different treatment plan
When Weight Loss Plateaus and How to Respond After approximately 16 to 24 weeks of tirzepatide treatment, some patients experience temporary weight loss plateausperiods of one to three weeks with minimal scale movement
Would recommend
Similarly, understanding proper injection technique and injection site selection can minimize side effects that contribute to dehydration
